We previously demonstrated that achieving and maintaining ≥7% weight loss at one year in patients with diabetes (DM), through multidisciplinary intensive lifestyle intervention (ILI) in real-world clinical practice, predicts improvement in cardiometabolic outcomes at 5 and 10 years. In this prospective follow-up, we report 15-year results. We evaluated 122 patients with DM and obesity (mean age 53.2±10.0 years, 68% females, 90.2% type 2, mean DM duration 9.1±8.6 years, mean BMI 38.4±5.2 kg/m²) who underwent 12 weeks of ILI. The total cohort lost in average 10.7±4.6 kg (-9.6%, p<0.001) after 12 weeks. At 1 year, they were divided into group A, who maintained <7% weight loss (47.5%), and group B, who maintained ≥7% weight loss (52.5%). At 15 years, average weight loss in the entire cohort was 8.6±11.9 Kg (-7.6%, p<0.001). Group A maintained an average weight loss of 3.9±6.5 kg (-3.6%) at 5 years, 3.8±9.4 kg (-3.9%) at 10 years and 3.8±10.0 kg (-4.0%) at 15 years. Group B maintained an average weight loss of 10.6±9.8 kg (-9.1%) at 5 years, 10.8±9.6 kg (-9.3%) at 10 years and 12.9±12.0 Kg (-11.0%) at 15 years. At 15 years, weight loss in group B remained significantly higher than in group A (p<0.001). In group A, A1C reduced from 7.5±1.4% to 6.7±0.9% at 12 weeks, but rebounded to 8.0±1.9% at 5 years and 10 years and was 7.9±1.8% at 15 years. In group B, A1C decreased from 7.3±1.1% to 6.3±0.8% at 12 weeks, and was 7.4±1.6% at 5 years, 7.2±1.4% at 10 years and 7.3±1.5% at 15 years (p=0.04 between groups). Both groups maintained significant improvements in LDL- and HDL-cholesterol at 15 years, but group A had significant worsening of their serum triglycerides. Both groups had nonsignificant changes in blood pressure at 15 years. In conclusion, ILI in real-world clinical practice that results in ≥7% weight loss at one year in patients with DM and obesity is associated with continued improvement in cardiometabolic outcomes at 15 years.

Disclosure

A.Khater: None. M.Al-badri: None. T.Salah: None. S.E.Dhaver: None. K.Kibaa: None. R.Mccarragher: None. O.Hamdy: Advisory Panel; Abbott Nutrition, Nemaura Medical, L-Nutra Inc., Twin Health, Consultant; Sanofi, Research Support; Novo Nordisk, Eli Lilly and Company, Gilead Sciences, Inc., Stock/Shareholder; Healthimation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.